Recursion Pharmaceuticals
Publicly traded AI drug discovery company that merged with Exscientia in a $688M all-stock deal (closed Nov 2024), combining biological screening (Recursion) with precision chemistry/automated synthesis (Exscientia).
This is where the depth lives — everything below is evidence-graded
How the product is positioned
Publicly traded AI drug discovery company that merged with Exscientia in a $688M all-stock deal (closed Nov 2024), combining biological screening (Recursion) with precision chemistry/automated synthes
Our summary of the vendor’s positioning — verbatim claim not yet recordedWhat we found
Level 1 · assistive
Seeded at the rubric default. No independent evidence of end-to-end task completion has been reviewed yet, so the lowest grade applies until it is.
Any human checkpoint here is a product setting, not a regulatory requirement — confirm how it is configured for your deployment.
Graded 2026-08-01 · re-check 2026-11-01
Procurement detail
- Deployment
- saasvendor documentation
- Compliance
- GxP-aligned R&D processesreport dates not disclosed — request before signing
- Integrations
- Internal automated wet-lab and computational infrastructure claim unverified
- Pricing
- customRevenue from pharma partnerships and milestone/royalty deals; not consumer-priced.
- Human checkpoint
- Requiredproduct setting
- Named customers
- Multiple pharma partners across 10+ partnered programs (not individually detailed in sources)from cited sources
Will they still be here?
- Funding
- NASDAQ: RXRX; merged with Exscientia ($688M all-stock deal, closed Nov 2024); $450M+ in partner milestone payments received to date
- Founded
- 2013
- HQ
- Salt Lake City, USA
Sources
Logo retrieved 2026-08-01from the vendor’s own site · trademark of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX)
- ir.recursion.comVendor-published · retrieved 2026-08-01
- fiercebiotech.comIndependent · retrieved 2026-08-01
Where it’s weak
Post-merger integration risk and pipeline rework reported months after the deal closed; public-market scrutiny on cash burn versus pipeline progress.
Corrections
Vendors may submit factual corrections free of charge. We correct facts and publish the change. We do not accept payment to change a grade. Submit a correction →